Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siHSP47-NP
- Development stage
- Preclinical
- Lead developer
- PDX Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal
01
Overview
**siHSP47-NP** is a preclinical, intradermally administered antifibrotic nanoparticle therapy developed by PDX Pharmaceuticals for scleroderma-associated skin fibrosis. It uses PDX-NP, a mesoporous silica nanoparticle with polyethylenimine and polyethylene glycol coatings, to deliver a small interfering RNA directed against heat shock protein 47. HSP47 silencing is intended to reduce collagen processing and fibrotic matrix accumulation, while the antioxidant silica core scavenges reactive oxygen species and is associated with reduced NADPH oxidase 4 and other profibrotic markers in preclinical models. In a bleomycin-induced mouse model of scleroderma, the product reduced HSP47 expression and dermal thickness. ([pdxpharm.com](https://www.pdxpharm.com/sihsp47-np/))
- Other names
- siHSP47-nanoparticlessiHSP-47-nanoparticlessiHSP 47-nanoparticles
02
Targets
HSP47 (Heat shock protein 47)NOX4 (NADPH oxidase 4)
Beyond the preview
Go deeper on siHSP47-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siHSP47-NP.